人类胰岛素製剂市场：按产品类型、按应用、按地区

预计2024年全球人类胰岛素製剂市场规模为524.7亿美元，预计2031年将达926.3亿美元，2024年至2031年复合年增长率为8.5%。

图 1. 2024 年人类胰岛素製剂市场占有率（%），依地区划分

由于世界各地糖尿病盛行率不断上升，过去几年全球人类胰岛素製剂市场稳定成长。人类胰岛素製剂是正常人类胰岛素的生物合成版本，用于治疗和管理糖尿病。根据国际糖尿病联盟发布的资料，2019年约有4.63亿成年人患有糖尿病，预计2045年将增加至7亿人。糖尿病人口的不断增长、胰岛素治疗意识的提高以及胰岛素笔和胰岛素帮浦等创新胰岛素输送系统的推出预计将推动全球对人类胰岛素产品的需求。

市场动态：

人类胰岛素製剂的全球市场成长主要是由于肥胖、久坐的生活方式、人口老化和遗传因素导致的糖尿病盛行率不断上升所推动。据世界卫生组织称，糖尿病是导致死亡的主要原因之一，估计每年有 150 万人死于糖尿病。人们对胰岛素治疗和胰岛素给药的各种创新药物输送选择（例如胰岛素帮浦和笔）的认识不断提高，可能会推动市场成长。然而，人类胰岛素製剂的高价格可能会阻碍市场成长。生物相似药人类胰岛素製剂市场的开拓为参与企业提供了利润丰厚的成长机会。

本研究的主要特点

• 该报告对全球人类胰岛素製剂市场进行了详细分析，并提供了以2023年为基准年的预测期（2024-2031年）的市场规模（十亿美元）和年复合成长率（CAGR%）。
• 它还揭示了各个细分市场的潜在收益成长机会，并说明了该市场有吸引力的投资提案矩阵。
• 它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的重要见解。
• 它根据公司亮点、产品系列、主要亮点、财务表现和策略等参数，介绍了全球人类胰岛素製剂市场的主要企业。
• 主要企业包括赛诺菲、诺和诺德公司、Biocon Limited、辉瑞公司、礼来公司、Wockhardt Ltd.、SEDICO、Exir、Aventis、Merck &Co., Inc.、Julphar、GLENMARK PHARMACEUTICALS LTD.、Boehringer 包括 Ingelheim国际有限公司、Mylan NV 等
• 该报告的见解使负责人和公司经营团队能够就未来的产品发布、类型升级、市场扩张和行销策略做出明智的决策。
• 全球人类胰岛素製剂市场迎合了该行业的各种相关人员，如投资者、供应商、产品製造商、经销商、新进业者和财务分析师。
• 透过分析全球人类胰岛素製剂市场时所使用的各种策略矩阵，将促进相关人员的决策。

目录

第一章 研究目的与前提

• 研究目标
• 先决条件
• 简称

第二章 市场展望

• 报告说明
  • 市场定义和范围
• 执行概述
• 一致的机会地图 (COM)

第三章市场动态、法规及趋势分析

• 市场动态
  • 促进因素
  • 抑制因素
  • 机会
• 影响分析
• 市场趋势
• 监管场景
• 製造商收益
• 收购和合作场景
• 产品发布/核准
• 资金筹措和投资
• PEST分析
• 波特的分析

第四章全球人类胰岛素製剂市场 - 冠状病毒（COVID-19）大流行的影响

• 整体影响
• 政府倡议
• COVID-19 对市场的影响

第五章全球人类胰岛素製剂市场，依产品类型，2019-2031（十亿美元）

• 介绍
• 人类胰岛素
• 基础胰岛素
• Bolus胰岛素
• 多重胰岛素
• 胰岛素生物相似药

第六章全球人类胰岛素製剂市场，按类型，2019-2031（十亿美元）

• 介绍
• 短效
• 长效

第七章 全球人类胰岛素製剂市场，依应用分类，2019-2031 年（十亿美元）

• 介绍
• 1型糖尿病
• 2型糖尿病

第八章全球人类胰岛素製剂市场，按地区，2019-2031（十亿美元）

• 介绍
• 拉丁美洲
• 欧洲
• 亚太地区
• 中东

第9章 竞争格局

• 公司简介
  • Sanofi
  • Novo Nordisk A/S
  • Biocon Limited
  • Pfizer Inc.
  • Eli Lilly and Company
  • Wockhardt Ltd.
  • SEDICO
  • Exir
  • Aventis
  • Merck &Co., Inc.
  • Julphar
  • GLENMARK PHARMACEUTICALS LTD.
  • Boehringer Ingelheim International GmbH.
  • Mylan NV

第10章分析师建议

• 升起和降落
• 综合机会图

第十一章 参考文献与调查方法

• 参考
• 调查方法

Global human insulin drug market is estimated to be valued at USD 52.47 Bn in 2024 and is expected to reach USD 92.63 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 8.5% from 2024 to 2031.

Figure 1. Human Insulin Drug Market Share (%), By Region, 2024

Global human insulin drug market has been witnessing steady growth over the past few years, owing to increasing prevalence of diabetes across the world. Human insulin drugs are biosynthetically manufactured versions of regular human insulin that is used for the treatment and management of diabetes. According to the data published by the International Diabetes Federation, approximately 463 million adults lived with diabetes in 2019 and the number is expected to rise to 700 million by 2045. Growing diabetic population, rising awareness about insulin therapy, introduction of innovative insulin drug delivery systems such as insulin pens and pumps are expected to boost demand for human insulin drugs globally.

Market Dynamics:

Global human insulin drug market growth is primarily driven by growing incidence of diabetes owing to obesity, sedentary lifestyle, aging population, and genetic factors. According to WHO, diabetes is one of the major causes of death with an estimated 1.5 million deaths caused by diabetes every year. Rising awareness about insulin therapy and various innovative drug delivery options for insulin administration such as insulin pumps and pens can drive the market growth. However, high cost of human insulin drugs can hamper the market growth. The development of biosimilar human insulin drugs provides lucrative growth opportunities for players in the market.

Key Features of the Study:

• This report provides an in-depth analysis of the global human insulin drug market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
• It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global human insulin drug market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this includes Sanofi, Novo Nordisk A/S, Biocon Limited, Pfizer Inc., Eli Lilly and Company, Wockhardt Ltd., SEDICO, Exir, Aventis , Merck & Co., Inc., Julphar, GLENMARK PHARMACEUTICALS LTD., Boehringer Ingelheim International GmbH, Mylan N.V.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global human insulin drug market caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global human insulin drug market

Detailed Segmentation-

• By Product Type:
  • Human Insulin
  • Basal Insulin
  • Bolus Insulin
  • Insulin Combinations
  • Biosimilar Insulins
• By Type:
  • Short Acting
  • Long Acting
• BY Application:
  • Type 1 Diabetes
  • Type 2 Diabetes
• By Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • Sanofi
  • Novo Nordisk A/S
  • Biocon Limited
  • Pfizer Inc.
  • Eli Lilly and Company
  • Wockhardt Ltd.
  • SEDICO
  • Exir
  • Aventis
  • Merck & Co., Inc.
  • Julphar
  • GLENMARK PHARMACEUTICALS LTD.
  • Boehringer Ingelheim International GmbH
  • Mylan N.V.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Product Type
  • Market Snapshot, By Type
  • Market Snapshot, By Application
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Opportunities
• Impact Analysis
• Market Trends
• Key Developments
• Regulatory Scenario
• Manufacturer Revenue
• Acquisitions and Partnerships Scenario
• Product Launches/Approvals
• Funding and Investments
• PEST Analysis
• Porter's Analysis

4. Global Human Insulin Drug Market - Impact of Coronavirus (COVID-19) Pandemic

• Overall Impact
• Government Initiatives
• COVID-19 Impact on the Market

5. Global Human Insulin Drug Market, By Product Type, 2019 - 2031, (USD Bn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Human Insulin
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Basal Insulin
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Bolus Insulin
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Insulin Combinations
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Biosimilar Insulins
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

6. Global Human Insulin Drug Market, By Type, 2019 - 2031, (USD Bn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Short Acting
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Long Acting
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

7. Global Human Insulin Drug Market, By Application, 2019 - 2031, (USD Bn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Type 1 Diabetes
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Type 2 Diabetes
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

8. Global Human Insulin Drug Market, By Region, 2019 - 2031, (USD Bn)

• Introduction
  • Market Share Analysis, By Region, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, For Region, 2020-2031
  • Regional Trends
    • North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
    • GCC
    • Israel
    • Rest of Middle East
    • Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
  • Forecast, and Y-o-Y Growth, and Y-o-Y Growth, By Country/Region, 2019 - 2031, (USD Bn)
    • North Africa
    • Central Africa
    • South Africa

9. Competitive Landscape

• Company Profiles
  • Sanofi*
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Novo Nordisk A/S
  • Biocon Limited
  • Pfizer Inc.
  • Eli Lilly and Company
  • Wockhardt Ltd.
  • SEDICO
  • Exir
  • Aventis
  • Merck & Co., Inc.
  • Julphar
  • GLENMARK PHARMACEUTICALS LTD.
  • Boehringer Ingelheim International GmbH.
  • Mylan N.V.

10. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

11. References and Research Methodology

• References
• Research Methodology
• About us and Sales Contact